A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
A phase 3 trial of Disitamab vedotin, Tislelizumab, Capecitabine, Oxaliplatin, Trastuzumab and Pembrolizumab in gastric & gastro-oesophageal junction cancer, run by RemeGen Co., Ltd., now recruiting.
Overview
A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. is a phase 3 interventional study registered as NCT07315750 by RemeGen Co., Ltd., with 555 participants planned, started 2026-01-01 and due to reach its primary completion in 2029-06-30. Interventions recorded: Disitamab Vedotin, Tislelizumab, CAPOX (oxaliplatin/capecitabine), Trastuzumab and Pembrolizumab.
Similar pages
not linked directly; found by shared links- TrialPerioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
Shares RemeGen, Disitamab vedotin, Oxaliplatin, Capecitabine and the tag pipeline.
- TrialA Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer
Shares RemeGen, Oxaliplatin, Capecitabine, Trastuzumab and the tag pipeline.
- TrialA Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States
Shares Tislelizumab, Oxaliplatin, Capecitabine, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialDV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
Shares RemeGen, Disitamab vedotin, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialA Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
Shares RemeGen, Disitamab vedotin, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialA Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]
Shares Tislelizumab, Oxaliplatin, Capecitabine and the tag pipeline.
- TrialPh1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
Shares Oxaliplatin, Capecitabine, Trastuzumab, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialTo Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2
Shares RemeGen, Disitamab vedotin and the tag pipeline.